A Randomized Trial of the “Polypill” for Cardiovascular Risk Modification

Long-term use of recommended cardiovascular (CV) risk modifying medications is low among patients at high-risk for CV events.  Fixed-dose drug combination (FDC) therapy may reduce treatment gaps by lowering non-adherence, cost, complexity and therapeutic inertia. However, FDC may also reduce tailoring of individual medications and thereby lead to suboptimal risk control. The UMPIRE (Use of […]

Read More…